8-K: Quanterix Invests Up to $30 Million in Akoya Biosciences via Convertible Notes

Quanterix Corporation has agreed to purchase up to $30 million in convertible promissory notes from Akoya Biosciences to support Akoya's working capital needs, contingent on certain conditions and the potential closing of their merger agreement.

Summary

• Quanterix Corporation has entered into a securities purchase agreement with Akoya Biosciences, Inc., where Quanterix will purchase convertible promissory notes from Akoya with an aggregate principal amount of up to $30 million.
• Akoya can draw on these notes between May 15, 2025, and July 9, 2025, or potentially until January 9, 2026, depending on the status and any extensions of their merger agreement.
• The convertible notes will mature 91 days after the earlier of November 1, 2027, or the date Akoya's existing loan agreement is repaid in full.
• The notes will bear interest at SOFR plus a specified margin, payable monthly, and can be converted into Akoya common stock if the merger agreement is terminated.
• Conversion is subject to a limit of 19.99% of Akoya's common stock prior to stockholder approval and includes anti-dilution provisions.
• Akoya must file a registration statement for the resale of shares issued upon conversion by August 13, 2025.
• The convertible notes will be subordinate to Akoya's existing loan agreement with MidCap Financial Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The investment provides Akoya with needed capital, and Quanterix has structured the deal to potentially benefit from Akoya's future success, either through the merger or equity conversion. However, risks remain regarding the merger's completion and Akoya's ability to repay the debt.

Positives

• Quanterix secures a potential return on investment through interest payments and potential equity conversion.
• Akoya gains access to additional funding to support its operations and working capital.
• The structure of the agreement provides flexibility for both companies depending on the outcome of the merger agreement.

Negatives

• Quanterix's investment is contingent on the merger agreement not closing before May 15, 2025.
• The conversion of notes into equity is capped at 19.99% prior to stockholder approval, potentially limiting Quanterix's initial stake.
• The notes are subordinate to Akoya's existing debt, increasing the risk for Quanterix in case of Akoya's financial distress.

Risks

• The merger agreement between Quanterix and Akoya may not be completed.
• Akoya may not be able to repay the convertible notes.
• The value of Akoya's common stock may decline, reducing the potential return on conversion.
• The subordination agreement places Quanterix in a secondary position to MidCap Financial Trust.
• The Nasdaq 19.99% cap may limit the number of shares issuable upon conversion without stockholder approval.

Future Outlook

The investment is contingent on the status of the merger agreement between Quanterix and Akoya, with the potential for Quanterix to acquire equity in Akoya if the merger is terminated and the notes are converted.

Industry Context

This announcement reflects a strategic investment within the life sciences tools and diagnostics sector, where companies often collaborate or merge to expand their technology platforms and market reach.

Comparison to Industry Standards

• Convertible note financing is a common tool in the biotech and life sciences industry, often used to bridge funding gaps or facilitate mergers and acquisitions.
• Similar deals include [hypothetical example] Company X's $25 million convertible note investment in Company Y to support clinical trials, with terms including a similar conversion cap and interest rate structure.
• The SOFR-based interest rate is in line with current market trends for debt financing.
• The subordination to existing debt is a typical arrangement, reflecting the lender's existing security and priority.

Stakeholder Impact

• Akoya's shareholders may experience dilution if the convertible notes are converted into common stock.
• Akoya's employees benefit from the company's increased financial stability.
• Quanterix's shareholders are exposed to the risks and potential rewards of the investment in Akoya.
• Akoya's customers and suppliers benefit from the company's ability to continue operations.

Next Steps

• Akoya needs to draw on the convertible notes within the specified timeframes.
• Akoya must file a registration statement for the resale of shares issued upon conversion by August 13, 2025.
• Quanterix and Akoya will need to monitor the progress of the merger agreement.
• Akoya may need to seek stockholder approval for the issuance of shares exceeding the 19.99% cap.

Key Dates

Keywords

Quanterix, Akoya Biosciences, convertible notes, securities purchase agreement, merger agreement, financing, investment, SOFR, registration rights, subordination agreement